IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Boehringer to Acquire California Biotech Firm

1:35 PM MDT | June 30, 2008 | Deepti Ramesh

Boehringer Ingelheim says it has agreed to acquire privately owned biopharmaceutical company Actimis Pharmaceuticals (San Diego) for as much as $515 million, depending on the successful development of an Actimis asthma drug. The deal is to be done in phases, depending on the progress of the asthma compound AP768, which is in phase 1 of clinical development. If AP768 successfully advances into phase III, Boehringer Ingelheim will own 100% of Actimis’ shares, Boehringer Ingelheim says. Actimis focuses on R&D of small-molecule therapeutics for severe...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa